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ABSTRACT  
Treatment of patients with advanced medullary thyroid carcinoma (MTC) is still a challenge. For 
more than 2 decades it is known that cholecystokinine-2 receptor (CCK2R) is a promising target 
for the treatment of MTC with radiolabeled minigastrin analogues. Unfortunately, kidney toxicity 
precluded their therapeutic application so far. In 6 consecutive patients we evaluated with 
advanced 3D dosimetry whether improved minigastrin analogue 177Lu-DOTA-(DGlu)6-Ala-Tyr-
Gly-Trp-Nle-Asp-PheNH2 (177Lu-PP-F11N) is a suitable agent for the treatment of MTC. 
Methods: Patients received two injections of about 1 GBq (~80 µg) 177Lu-PP-F11N with and 
without a solution of succinylated gelatin (SG, a plasma expander used for nephroprotection) in 
a random cross-over sequence in order to evaluate biodistribution, pharmacokinetics as well as 
tumor- and organ dosimetry. Electrocardiogram, blood count and blood chemistry were 
measured up to 12 weeks after administration of 177Lu-PP-F11N to assess safety. Results: In all 
patients 177Lu-PP-F11N accumulation was visible in tumor tissue, stomach and kidneys. 
Altogether 13 tumors were eligible for dosimetry. The median (interquartile range = IQR) 
absorbed dose for tumors, stomach, kidneys and bone marrow was 0.88 Gy/GBq (0.85-1.04), 
0.42 (0.25-1.01), 0.11 (0.07-0.13) and 0.028 (0.026-0.034). These resulted in a median (IQR) 
tumor-to-kidney dose ratio of 11.6 (8.11-14.4) without SG and 13.0 (10.2-18.6) with SG, which 
was not significantly different (P = 1.0). The median (IQR) tumor-to-stomach dose ratio was 3.34 
(1.14-4.7). Adverse reactions (mainly hypotension, flushing and hypokalemia) were self-limiting 
and not higher than grade 1. Conclusion: 177Lu-PP-F11N accumulates specifically in MTC at a 
dose that is sufficient for a therapeutic approach. With little kidney and bone marrow radiation 
dose 177Lu-PP-F11N shows a promising biodistribution. The dose limiting organ is most likely the 
stomach. Further clinical studies are necessary to evaluate the maximum tolerated dose and the 
efficacy of 177Lu-PP-F11N. 
Key words: Cholecystokinine-2 receptor targeting, PRRT, 177Lu-PP-FF11N, Theranostics 
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INTRODUCTION 
According to recent data from the Surveillance, Epidemiology, and End Results database, 
medullary thyroid cancer (MTC) represents 1-2% of all thyroid cancers in the United States. 
Distant metastases can be detected clinically in 4-17% of patients at the time of diagnosis (1,2). 
MTC lacks accumulation of radioactive iodine and cytotoxic chemotherapy shows disappointing 
results for advanced MTC (1). The kinase inhibitors Vandetanib and Cabozantinib are approved 
for the treatment of MTC (3,4), but have not shown a significant effect on overall survival and 
may cause significant adverse reactions, including QT prolongation. Radionuclide therapy with 
compounds such as 90Y-DOTATOC and Iodine-131 pretargeted anti-carcinoembryonic-antigen 
radioimmunotherapy were published in 2006/2007 with promising results (5,6). However, they 
were not introduced in clinical routine so far.  Therefore, there is an unmet need for a more 
effective systemic therapy for patients with advanced MTC. 
Specific targeting of MTC cells with radiolabeled minigastrin analogues has the potential to 
improve imaging and to allow peptide receptor radionuclide therapy, as >90% of MTC express 
the transmembrane G-protein coupled cholecystokinine-2 receptor (CCK2R) at a high density 
(7). Eight patients with advanced MTC were treated in a pilot study with the CCK2R specific 
yttrium-90 labeled minigastrin analogue 90Y-DTPA-Glu1-minigastrin (8). This resulted in partial 
remission in four and stable disease in two patients, lasting for up to 36 months. Unfortunately, 
nephrotoxicity and bone marrow toxicity limited the therapeutic application of this first 
radiolabeled minigastrin analogue.  
Co-injection of nephroprotective substances is an often used approach to reduce 
nephrotoxicity. This was evaluated in rats and showed promising results with a 4% succinylated 
gelatin solution (SG, international marketing authorization as plasma expander: Gelofusine®, 
respectively Physiogel®). SG resulted in a 45% reduction of the renal cortex uptake of 111In-
DTPA-Glu1-minigastrin (9), whereas the cationic amino acid lysine did not show a significant 
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effect. Another approach to reduce nephrotoxicity is to modify the compound itself: Amino acid 
chains with more than 5 glutamic acids in their sequence play an important role in the kidney re-
uptake mechanism and may reduce kidney uptake (10,11). Such an approach was implemented 
by several groups and resulted in the development of a library of improved radiolabeled 
minigastrin analogues (12-17). Some of these new compounds show higher tumor uptake, 
higher tumor-to-kidney uptake ratios and higher serum stability, compared to the previously 
developed minigastrin analogues. One of the most promising new compounds is PP-F11N 
(DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Nle-Asp-PheNH2) which can be labeled with Lutetium-177, a 
widely used radionuclide that has not only excellent therapeutic properties but also a gamma ray 
component that allows acquisition of good quality images for a personalized treatment approach 
(theranostics), as well as dosimetry studies (16).  
Here, we present the first-in-human results of 177Lu-PP-F11N. Primary endpoint was the proof 
of CCK2R specific in vivo targeting and visualization of MTC metastases in correlation with 
histology, in vitro autoradiography or 18F-DOPA PET/CT as standard of comparison. Secondary 
endpoints were safety, biodistribution, pharmacokinetics and radiation dosimetry after injection 
of a test dose of 177Lu-PP-F11N with SG and without kidney protection in the same patient in a 
random cross-over order. 
 
MATERIALS AND METHODS 
Study Design and Patients 
This is a prospective, randomized cross-over phase 0 single center study (clinicaltrials.gov: 
NCT02088645). The study was approved by the Institutional Review Board and all patients 
signed a written informed consent in accordance with the Declaration of Helsinki.  
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The main inclusion criteria were: histologically confirmed MTC with or without thyroidectomy 
and either elevated levels of calcitonin (> 100 pg/ml; respectively 29.2 pmol/l) and/or calcitonin-
doubling time < 24 months. Patients who had received Vandetanib less than 3 weeks before the 
study and patients with reduced kidney or bone marrow function (calculated glomerular filtration 
rate < 60 ml/min / 1.73 m2 body surface, thrombocytes < 70’000/μl, leucocytes < 2’500/μl, 
hemoglobin < 8 g/dl) were not included.  
Preparation of 177Lu-PP-F11N 
177Lu-PP-F11N was produced according to good manufacturing practice by the Paul Scherrer 
Institute Villigen, Switzerland. The precursor peptide PP-F11N (2031.5 g/mol, GMP grade 
quality, piCHEM GmbH, Graz, Austria) is carrying a DOTA moiety on its N-terminal end, which 
allows stable chelation of Lutetium-177. GMP grade no carrier-added 177LuCl3 (EndolucinBeta) 
was provided by ITG Isotope Technologies Garching GmbH, Garching, Germany. Radiolabeling 
of 177Lu-PP-F11N was done in a synthesis module (PharmTracer by Eckert & Ziegler, Berlin, 
Germany). The reaction mixture, composed of 100 µg PP-F11N in aqueous 0.25 M ammonium-
acetate buffer pH 5.5 (trace pure reagents, Sigma Aldrich, Buchs, Switzerland) and sodium 
ascorbate (USP grade) was incubated for 40 min at 60 °C with 1.7 GBq of EndolucinBeta. The 
reaction mixture was purified via C-18 SepPak column and sterile filtered into a bulk vial. The 
bulk product contained 20.9 mL 0.9 % saline, 1.25 mL ethanol, 1.75 mL water for injection, 0.1 
ml DTPA (200 mg/mL), 250 mg sodium-ascorbate and 177Lu-PP-F11N (total volume of 24 mL). 
After dispensing via a second sterile filter and taking aliquots for QC, the resulting product vial 
contained 20 ± 2 mL of final product tested for compliance with specifications (radiochemical 
purity: ≥ 95%; 177Lu-DTPA: ≤ 2%; peptide content: < 100 µg of total PP-F11N; endotoxins: ≤ 175 
EU). The product contained about 1 GBq of radioactivity at the end of shelf life, which is 24 h. 
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Injection 
Patients received about 1 GBq 177Lu-PP-F11N with and without SG in a random cross-over 
order within 4 weeks. Administration of SG (Physiogel®, B. Braun Medical AG, Sempach, 
Switzerland) was performed according to the IAEA, EANM, SNMMI guideline for PRRT (18), 
starting with a bolus dose of 6 ml/kg body weight/min 10 min before the start of the injection of 
177Lu-PP-F11N. After termination of 177Lu-PP-F11N infusion, SG infusion was continued at a 
lower rate of 0.02 ml/kg body weight/min for 3 h. 
Vital signs were recorded for 24 h and a 12-lead electrocardiogram was done before and 2 h 
after each injection. Clinical laboratory tests (hematology, biochemistry) were assessed until 12 
weeks after the second injection. Adverse events were recorded and graded according to 
CTCAE 4.03. 
Biodistribution, Pharmacokinetics and Dosimetry 
Whole-body planar images and SPECT from neck to pelvis were performed on a calibrated 
SPECT/CT scanner (Symbia Intevo; Siemens Healthcare) at 1, 4, 24 and 72 h p.i. A combined 
SPECT/CT was acquired 24 h p.i. with a low-dose non-enhanced CT (130 kVp, 40 mA) for 
attenuation correction, anatomical reference and measurement of tumor diameters. The 
SPECT/CT scanner was equipped with a medium-energy, parallel-hole collimator and calibrated 
to a Selenium-75 source (Siemens Healthcare). Image acquisition was done with 2 detectors: 
180° rotation per detector, 64 projections per detector, 20 s and 24 s (late scan at 72 h) per 
projection in a 128x128 matrix. The energy windows were set to 208 keV and 113 keV with a 
window width of 20 %. After data acquisition in list mode, a prototype version of xSPECT Quant 
(Siemens Healthcare) was used for Lutetium-177 quantification in order to get attenuation and 
scatter corrected quantitative datasets for 3D dosimetry studies. 
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Dosimetry of tumors, stomach and kidneys with and without co-administration of SG was 
performed with the Siemens Dosimetry Research Tool software version 5.4 (DRT, Siemens 
Medical Solutions, USA). DRT enables two methods for calculation of radiation dose: Voxel-
based 3D dose kernel approach and a volume-based MIRD procedure, using quantitative 
SPECT/CT datasets with volumes of interest (VOIs) to create a time-activity fit (19). In our study 
the more established volume-based MIRD procedure was used.   
177Lu-PP-F11N positive tumors were identified on SPECT and correlated with the CT images.  
Afterwards, tumor VOIs were drawn based on CT volume. For kidney dosimetry, VOIs were 
defined on CT images by an automated segmentation algorithm. If necessary, contours were 
corrected manually, excluding the renal calices. Dosimetry of the stomach was hindered by 
stomach movement. To overcome this problem, a conservative measurement was chosen: a 
VOI of constant volume per patient (median 3.8 ml, range 1.9-25.6 ml) was placed over the 
stomach wall at the level of the maximum uptake across all time points in order to obtain 
residence time values (time-activity-fit) of the stomach wall. Residence time values of the 
stomach wall, kidneys and tumors were multiplied with S values (Monte Carlo simulations) and 
corrected for effective volumes. Tumor radiation doses were corrected for the partial volume 
effect, using recovery coefficients. Recovery coefficients were obtained by measurement of a 
NEMA NU 2007 phantom with a known activity concentration inside spheres of various 
diameters (smallest diameter was 10 mm which corresponds to a sphere of 0.52 cm3). Recovery 
coefficients for tumor volumes lying between the measured sphere volumes were estimated by 
linear interpolation. 
OLINDA/EXAM 1.0 software (Vanderbilt University, TN, USA) was used for the radiation dose 
calculation of the large intestine, bladder and the red bone marrow, see supplemental data. This 
is a 2D method based on planar images or blood sampling, using a blood-to-red-marrow activity 
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concentration ratio of 1, as recommended by the European Association of Nuclear Medicine 
(20). 
Standard for Comparison 
177Lu-PP-F11N SPECT/CT scans were compared either with 18F-DOPA (18F-fluorodopa) 
PET/CT scans or histology, including in vitro autoradiography. 18F-DOPA PET with contrast 
enhanced CT was performed 29-36 min after injection of 2.1-4.6 MBq/kg 18F-DOPA according to 
the EANM guidelines (21) without carbidopa pretreatment in a time interval ranging from 7 
months before until 3 months after performing the first 177Lu-PP-F11N scan.  
Fresh frozen tissue samples of one patient were available for in vitro autoradiography. In vitro 
CCK2R autoradiography was performed as described before (7). The sections were incubated 
with 6 x 105 cpm/ml of indium-111 labeled PP-F11N (45 MBq/nmol). In order to assess non-
specific binding, an adjacent section of the same specimen was incubated in tracer solution 
containing additionally 200 nM of non-radioactive human gastrin (BACHEM, Bubendorf, 
Switzerland). The slides were then exposed to Biomax MR films (Carestream Health, Stuttgart, 
Germany) for 4 days. For signal quantification, a separate calibration curve, based on standard 
samples containing known amounts of radioactivity was recorded for each experiment. 
Subsequently, the autoradiograms were analyzed using MCID software (InterFocus, Linton, UK). 
For histopathological evaluation and localization of autoradiographic signal, adjacent slices were 
hematoxylin-eosin-stained. 
Statistical Analysis 
All variables were analyzed descriptively. Paired sign t-test, with a p-value <0.05 denoting 
statistical significance, was used to compare results obtained with and without SG (matched 
pairs). 
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RESULTS  
Patients 
Six consecutive patients with histologically proven MTC were screened and participated in 
the study. They all completed the study and were included in the proof of principle, safety, 
pharmacokinetic and dosimetry evaluation. All patients have had thyroidectomy previously. For 
further baseline demography and disease characteristics see Supplemental Table 1.  
Proof of Principle 
After infusion of 1040 ± 70 MBq (mean ± standard deviation; range: 915-1226 MBq) 177Lu-PP-
FF11N focal uptake concordant with pathological lesions was visible on whole body scintigraphy 
and SPECT/CT in all patients (Figs. 1 and 2).  The median (IQR) volume of the tumors that 
underwent dosimetry was 0.72 cm3 (range 0.57-1.51). Comparison with 18F-DOPA PET/CT in 4 
patients and with histology in 2 patients confirmed tumor specific 177Lu-PP-F11N accumulation in 
all patients. Lesions identified with 177Lu-PP-F11N SPECT/CT showed good correlation with 18F-
DOPA PET/CT, as 41 of 49 18F-DOPA positive lesions were 177Lu-PP-F11N positive, too. On 
resected lesions from patient 3, in vitro autoradiography performed with 111In-PP-F11N and 
histological assessment showed proof of tumor specific, CCK2R-mediated 177Lu-PP-F11N 
accumulation in lymph node metastases (Fig. 3). One lymph node metastasis with a maximal 
diameter of 8 mm and 40% tumor involvement was not visible with SPECT/CT, but showed 
specific and  intense 111In-PP-FF11N uptake in vitro (Supplemental Fig. 1). The minimal size 
among detectable tumors with SPECT/CT was 8 mm, see Fig. 1. 
Safety, Pharmacokinetics and Dosimetry 
The short infusion (duration range: 4-6 minutes) of 79.3 ± 10.5 µg (mean ± SD, range: 67.0-
94.5 µg) 177Lu-PP-F11N was well tolerated with only grade 1 toxicity (Table 2). 
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Blood sampling of 177Lu-PP-F11N revealed a bi-exponential blood clearance with an α half-life 
of 11 ± 3.3 min (with SG) versus 10.8 ± 5.4 min (without SG) and a β half-life of 162 ± 12 min 
versus 163 ± 14 min (mean ± SD); approximately 45% of the administered activity was cleared 
in the α phase. SG infusion starting 10 min before injection of 177Lu-PP-FF11N did not 
significantly reduce renal absorbed dose: median (IQR) absorbed dose was 0.11 (0.07-0.13) 
Gy/GBq without SG and 0.06 (0.05-0.09) Gy/GBq with SG, p = 0.38 (two-sample paired sign 
test). The small amount of absorbed dose to the kidneys indicates low retention of 177Lu-PP-
F11N in the kidneys despite its predominant renal excretion (Fig. 2). The highest absorbed dose 
was determined for the tumors and stomach: median (IQR) absorbed dose without SG was 0.88 
(0.85-1.04) Gy/GBq for tumors and 0.42 (0.25-1.01) Gy/GBq for the stomach, resulting in a 
median (IQR) tumor-to-stomach dose ratio of 3.34 (1.14-4.7), see Table 1. Blood sampling 
revealed a comparable median bone marrow dose with and without SG (0.032 and 0.028 
Gy/GBq, respectively, Table 1). A summary of dosimetry results of all organs is given in 
Supplemental Table 2. 
 
DISCUSSION 
The main findings of this phase 0 clinical trial can be summarized as follows: 1) 177Lu-PP-
F11N shows specific accumulation with sufficiently high radiation dose in MTC tissue, potentially 
allowing a therapeutic approach; 2) In vitro data using autoradiography are consistent with in 
vivo data; 3) Acute toxicity of 177Lu-PP-F11N is low; 4) dosimetry results suggest that the dose 
limiting organ is the stomach and 5) the co-administration of SG does not affect tumor-to-kidney 
dose ratio.  
Even though the injected activity was low (1 GBq), 177Lu-PP-F11N SPECT/CT imaging 
detected lesions in all patients. Forty-one of 49 18F-DOPA PET/CT positive lesions could also be 
identified with SPECT-imaging, with the smallest detected metastasis measuring only 8 mm, 
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confirming effective CCK2R targeting and low background activity with 177Lu-PP-F11N. In one 
177Lu-PP-F11N SPECT negative lesion, in vitro autoradiography showed 111In-PP-F11N specific 
accumulation in an 8 mm lymph node metastasis with 40% tumor infiltration. This example 
shows that even small SPECT negative metastases could potentially be treated with 177Lu-PP-
F11N. The tumor radiation doses calculated in our study are lower than those normally 
calculated for radionuclide therapy with Lutetium-177 labelled somatostatin-receptor subtype 2 
(SSTR2) specific ligands in patients with non-MTC neuroendocrine tumors. For example, the 
median tumor dose for 177Lu-PP-F11N in our study is 0.88 Gy/GBq versus 2.0 Gy/GBq for 177Lu-
DOTATATE in neuroendocrine tumors (22). On the other hand, in vitro autoradiography studies 
have shown a higher incidence of CCK2R than SST2R expression in MTC: iodine-125 labeled 
CCK2R agonist showed specific binding in >90% of MTC versus <30% with iodine-125 labeled 
SST2R agonist (7,23). Furthermore, radiation doses to organs such as kidneys and bone 
marrow were at least 3 times less with 177Lu-PP-F11N than with 177Lu-DOTATATE (22). Based 
on our dosimetry study, fractionated treatment with a cumulative activity of 50 GBq 177Lu-PP-
F11N should be possible without surpassing the maximal tolerated dose to the stomach, which 
is estimated to be 50 Gy based on external beam radiotherapy studies (24). Indeed, the 3rd 
quartile of the 177Lu-PP-F11N absorbed dose to the stomach was 1 Gy/GBq. A cumulative 
activity of 50 GBq could potentially result in a mean absorbed tumor dose of 50 x 0.9 Gy (~45 
Gy) or 50 x 3.6 Gy (~180 Gy) for patient 2, who showed the highest tumor absorbed dose.  
Acute toxicity after injection of 67.0-94.5 µg 177Lu-PP-F11N was low and within the range of 
adverse reactions known from the CCK2R agonist pentagastrine (calcitonin stimulation test) or 
other minigastrin analogues (8). Radiation induced toxicity was not observed after a cumulated 
activity of ~2 GBq 177Lu-PP-F11N.  
Calculated kidney radiation doses were low and resulted in higher median tumor-to-kidney 
radiation dose ratios, compared to the commonly used therapeutic radiotracer 177Lu-DOTATATE 
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(11.6 versus 1.6) (22). In contrast to DTPA-Glu1-minigastrin (9), the co-administration of SG did 
not significantly reduce the tumor-to-kidney dose ratio in our study. Therefore, nephroprotection 
with SG in combination with 177Lu-PP-F11N is not beneficial and can be omitted, as kidney 
doses are already low. The stomach received the highest calculated organ radiation dose and is 
therefore most likely the dose limiting organ. This has been reported for CCK2R ligands before 
(8) and can be explained by specific binding of 177Lu-PP-F11N to the CCK2R on neuroendocrine 
cells in the gastric mucosa, mainly enterochromaffine-like cells (25).  Interestingly, stomach 
radiation doses in our patients were heterogeneous (0.18 - 2.07 Gy/GBq). The patient with the 
highest stomach dose (patient 5) had history of medication with proton pump inhibitors. The 
patient with the lowest dose (patient 4) received enteral tube feeding formula. Therefore, it can 
be speculated that gastric acidity and activity (digestion) might have a relevant effect on the 
stomach uptake. This would be in line with reported increase of enterochromaffine-like cells 
density and the thickness of gastric mucosa after chronic acid suppression by proton pump 
inhibitors (25). Radiation doses of the remaining organs, including bone marrow, were low and 
therefore they were not considered as risk organs for a therapeutic approach.  
The evaluation of the different radiolabeled minigastrin derivatives differing in both, the C-
terminal peptide binding moiety and the structural characteristics of the linker, revealed that the 
compounds with six D-glutamic acid residues within the amino acid chain belong to the most 
promising substances with an reasonable balance of tumor uptake and decreased kidney 
reabsorption (11,12,16). The pronounced hydrophilicity of such compounds is most likely the 
reason for the fast renal excretion and shorter blood half-life of 177Lu-PP-F11N in comparison to 
177Lu-DOTATATE (β half-life of 163 ± 14  min versus 468 ± 150 min (mean ± SD)) (22), resulting 
in a lower tumor radiation dose. Future strategies to achieve higher tumor doses should be 
investigated and might consist in either increasing tumor uptake (e.g. by upregulation of CCK2R 
density selectively in MTC) or decreasing stomach uptake (e.g. via a specific diet or by 
manipulation of gastric acidity). 
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The main limitation of our study is the low number of evaluated subjects. This might affect the 
statistical significance of kidney dosimetry with and without SG. But even if SG has a significant 
nephroprotective effect, it appears unnecessary to expose patients to potentially severe SG-
related toxicity (i.e. anaphylactic reactions), as 177Lu-PP-FF11N shows per se low kidney uptake.  
 
CONCLUSION 
177Lu-PP-F11N accumulates specifically in MTC lesions, resulting in a radiation dose level 
that is potentially sufficient for a therapeutic approach. The biodistribution of 177Lu-PP-F11N 
appears to be favorable, with low kidney and bone marrow radiation dose. The dose limiting 
organ is most likely the stomach. Further clinical studies are necessary to evaluate the maximum 
tolerated dose and efficacy of 177Lu-PP-F11N in MTC and other CCK2R expressing tumors. In 
doing so, the following clinical scenarios should be considered: postoperative adjuvant approach 
in high risk patients and palliative treatment of advanced, metastatic disease. 
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KEY POINTS 
QUESTION: Is it possible to target medullary thyroid carcinoma (MTC) lesions with 177Lu-PP-
F11N in humans? 
PERTINENT FINDINGS: In a monocentric phase 0 proof of principle study, 177Lu-PP-F11N 
shows low toxicity and specific accumulation in MTC tissue accumulation in all 6 included 
patients. 
IMPLICATIONS FOR PATIENT CARE: 177Lu-PP-F11N is a promising and safe 
radiopharmaceutical for peptide receptor radiotherapy of MTC. 
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FIGURES 
   
FIGURE 1. 177Lu-PP-F11N SPECT/CT scans 24 h p.i. in coronar orientation. In all 6 patients (A-
F: patient 1-6), several tumors were visualized with SPECT (white arrows). Minimal diameter of 
a detectable tumor was 8 mm (F: patient 6). S = stomach, C = colon. 
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FIGURE 2. Planar scans (anterior view) of patient 2 without and with co-administration of 
succinylated gelatin (SG) at 1, 4, 24 and 72 h after injection of 1 GBq of 177Lu-PP-F11N. On 
planar scans two tumors with a diameter of 10 x 10 mm and 7 x 18 mm (black arrows) were 
visible. K: kidneys, C: colon, S: stomach, B: urinary bladder, U: urine contamination.  
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FIGURE 3. Images from patient 3, showing the axial 177Lu-PP-F11N SPECT/CT scan (A) of a 
suspicious lymph node (red arrow) with the corresponding hematoxylin-eosin-stained tissue (B) 
and in vitro autoradiograms of adjacent sections indicating total binding of 111In-PP-F11N (C) and 
non-specific binding (D). E and F show dog stomach tissue as a positive control. An 9 x 9 mm 
lesion with uptake in SPECT/CT (A) corresponds to a lymph node metastasis with 60% tumor 
cells (B) and specific 111In-PP-F11N binding (C and D). Red bars: 10 mm. See Supplemental 
Fig. 1 for additional series. 
 
by Universitaetsbibliothek Bern on January 8, 2020. For personal use only. jnm.snmjournals.org Downloaded from 
22 
 
TABLE 1. Absorbed radiation doses of 177Lu-PP-F11N in tumors, kidneys, stomach and bone marrow without and with co-administration 
of succinylated gelatin. 
*Test for superiority: two-sample paired sign test with a significance level, α, of 0.05. Abbreviation: SG = succinylated gelatin 
Patient Mean tumor dose 
(Gy/GBq) per 
patient 
Mean kidney 
dose (Gy/GBq) 
per patient 
Stomach dose 
(Gy/GBq) 
Bone marrow 
dose (Gy/GBq) 
Tumor-to-kidney 
dose ratio 
Tumor-to-stomach 
dose ratio 
Tumor-to-bone 
marrow dose ratio 
SG Without With Without With Without With Without With Without With Without With Without With 
 
1 1.09 1.04 0.15 0.11 0.45 0.50 0.022 0.025 7.27 9.45 2.42 2.08 49.6 41.6 
2 3.59 1.42 0.13 0.07 0.38 0.47 0.025 0.028 27.6 20.3 9.45 3.02 143.6 50.7 
3 0.90 0.67 0.06 0.05 1.66 1.46 0.028 0.031 15 13.4 0.54 0.46 32.1 21.6 
4 0.85 0.64 0.08 0.10 0.20 0.18 0.044 0.039 10.6 6.4 4.25 3.56 19.3 16.4 
5 0.85 1.03 0.13 0.05 1.2 2.07 0.036 0.039 6.5 20.6 0.71 0.50 23.6 26.4 
6 0.63 0.63 0.05 0.05 0.13 0.26 0.028 0.033 12.6 12.6 4.85 2.42 22.5 19.1 
Median 0.88 0.85 0.11 0.06 0.42 0.49 0.028 0.032 11.6 13 3.34 2.25 27.9 24 
IQR 0.85-
1.04 
0.65-
1.04 
0.07-
0.13 
0.05-
0.09 
0.25-
1.01 
0.31-
1.22 
0.026-
0.034 
0.025-
0.038 
8.11-
14.4 
10.2-
18.6 
1.14-
4.70 
0.90-
2.87 
19.3-
45.2 
16.4-
37.8 
Test for 
superiority* 
P = 0.38 P = 0.38 P = 0.69 P = 0.22 P = 1.0 P = 0.16 P = 0.22 
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TABLE 2. Adverse events (AE) observed following injection of 177Lu-PP-F11N 
Patient No.  AE without SG AE with SG Intensity* Relationship 
1 Hot flushes Hot flushes Grade 1 Probable 
 
2 Hot flushes 
Nausea and vomiting 
Paresthesia 
Toothache 
 
Fatigue 
Headache 
Hot flushes 
Nausea and vomiting 
Paresthesia 
Toothache 
Hypotension 
Grade 1 
Grade 1 
Grade 1 
Grade 1 
Grade 1 
Grade 1 
Grade 1 
Probable 
Probable 
Probable 
Probable 
Probable 
Possible 
Possible 
 
3 Numbness 
Hypotension 
 
Hypotension 
Grade 1 
Grade 1 
Probable 
Probable 
 
4 Nausea and vomiting 
Tachycardia 
 
Hypocalcemia 
Nausea and vomiting 
 
Hypotension 
 
Fatigue 
Hypokalemia 
Grade 1 
Grade 1 
Grade 1 
Grade 1 
Grade 1 
Grade 1 
Probable 
Probable 
Possible 
Possible 
Probable 
Probable 
5  
Hypocalcemia 
 
Nausea 
 
Abdominal pain 
Hot flushes 
Hypocalcemia 
Hypokalemia 
Nausea 
Dizziness 
Grade 1 
Grade 1 
Grade 1 
Grade 1 
Grade 1 
Grade 1 
Probable 
Probable 
Possible 
Probable 
Probable 
Possible 
 
6 Hypotension 
Hypokalemia 
Hypotension Grade 1 
Grade 1 
Probable 
Possible 
*Graded according to CTCAE (Common Terminology Criteria for Adverse Events) version 4.03. 
Abbreviation: SG = succinylated gelatin 
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Supplemental Data 
Cholecystokinin-2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of 
Medullary Thyroid Carcinoma - Results of the Lumed Phase 0a Study 
 
Dosimetry 
2D dosimetry was performed for the bladder (all patients) and large intestine, if visible at 
more than one time point on images, which was the case in one patient. For all imaging time 
points, regions of interest were manually drawn around the whole body, bladder and, if 
applicable, large intestine, on both the anterior and the posterior scans. Background regions 
were placed close to the regions of interest for background correction. The geometric mean 
value, between anterior and posterior, was taken and corrected for attenuation using the 
conjugate-view method. Whole-body activity acquired at 1 hour after injection of 177Lu-PP-
F11N was set as 100 percentage injected activity. Time-activity curves derived from the 
whole-body studies were analyzed with the OLINDA/EXAM 1.0 (Vanderbilt University, TN, 
USA) software. Organ doses were calculated with the OLINDA/EXAM 1.0 whole-body female 
and male phantom. For this calculation stomach and kidney numbers of disintegrations for 
the source organs were obtained from 3D dosimetry data. In doing so the gamma radiation 
cross-fire effect from stomach and kidneys to the other organs is considered. Blood marrow 
doses were determined by the blood-based red marrow dose methodology, which assumes a 
linear relation between the blood residence time and the red marrow residence time. For 
dosimetry calculations with OLINDA/EXAM 1.0 a blood-to-red-marrow activity concentration 
radio of 1 was used as recommended by the European Association of Nuclear Medicine. 
Final organ dosimetry results which are presented in Supplemental Table 2 are based on 
OLINDA/EXAM 1.0 calculations except stomach and kidneys which were done with 3D 
volume-based MIRD dosimetry as described in the Method part of the manuscript.   
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Supplementary Table 1. Patients’ demography and MTC characteristics 
Patient 
no. 
Age 
(y) 
Sex TNM Time after first 
diagnosis 
(months) 
Ct* before 
study enrollment 
(pg/ml) 
CEA* before 
study enrollment 
(µg/l) 
1 60 F pT4 N1 Mx  129 3150 15.5 
2 40 M pT3 N1b M1 7 5900 64.8 
3 54 F pT4 N1 M0 186 1272 24.5 
4 32 F Tx N1 M1 125 53694 1436 
5 67 M Tx N1 Mx 230 226 3.3 
6 46 M pT3 N1b 8 134 2.7 
*Abbreviations and normal laboratory values: Ct = calcitonin, normal value Ct < 8.6 pg/ml, 
CEA = carcinoembryonic antigen, normal value CEA < 3.4  µg/l 
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Supplementary Table 2. Absorbed organ and effective doses of 177Lu-PP-F11N without and 
with co-administration of succinylated gelatin. 
*Test for superiority: two-sample paired sign test with a significance level, α, of 0.05. † Not 
applicable as all patients had previous thyroidectomy. Abbreviation: SG = succinylated 
gelatin, LLI = lower large intestine; ULI = upper large intestine 
 
 
 
 
 
Organ/tissue Median absorbed radiation dose  
in Gy/GBq (IQR) 
Test for 
superiority* 
Without SG With SG P = 
Adrenals 0.0012   (0.0008-0.0021) 0.0011   (0.0008-0.0024) 1.00 
Brain 0.0000 0.0000  1.00 
Breasts 0.0002   (0.0001-0.0004) 0.0002   (0.0001-0.0005) 0.22 
Gallbladder wall 0.0011   (0.0008-0.0021) 0.0012   (0.0007-0.0029) 1.00 
LLI wall 0.0017   (0.0009-0.0025) 0.0011   (0.0010-0.0016) 0.38 
Small intestine 0.0013   (0.0009-0.0016) 0.0010   (0.0007-0.0021) 0.69 
Stomach wall 0.42       (0.25-1.01) 0.49       (0.31-1.22) 0.69 
ULI wall 0.0012   (0.0010-0.0019) 0.0011   (0.0008-0.0025) 1 
Heart wall 0.0007   (0.0005-0.0015) 0.0080   (0.0005-0.0021) 0.69 
Kidneys 0.11       (0.067-0.13) 0.062     (0.053-0.093) 0.38 
Liver 0.0006   (0.0004-0.0011) 0.0006   (0.0004-0.0015) 0.69 
Lungs 0.0004   (0.0003-0.0007) 0.0004   (0.0003-0.0011) 0.03 
Muscle 0.0007   (0.0005-0.0009) 0.0005   (0.0004-0.0011) 0.69 
Ovaries 0.0012   (0.0008-0.0017) 0.0010   (0.0009-0.0013) 0.69 
Pancreas 0.0035   (0.0022-0.0079) 0.0039   (0.0025-0.0010) 0.69 
Red marrow 0.0280   (0.026-0.034) 0.0320   (0.025-0.0375) 0.22 
Osteogenic cells 0.0066   (0.0053-0.0082) 0.0074   (0.0062-0.0088) 0.22 
Skin 0.0002   (0.0002-0.0003) 0.0002   (0.0001-0.0004) 0.13 
Spleen 0.0023   (0.0014-0.0051) 0.0025   (0.0016-0.0058) 0.69 
Testes 0.0002   (0.0-0.0004) 0.0002   (0.0-0.0004) 0.25 
Thymus 0.0001   (0.0001-0.0003) 0.0001   (0.0001-0.0004) 0.30 
Thyroid Not applicable † Not applicable †  
Urinary bladder wall 0.27        (0.22-0.37) 0.26        (0.23-0.32) 0.69 
Uterus 0.0018   (0.0015-0.0027) 0.0018   (0.0017-0.0020) 0.69 
Total body 0.0030   (0.0023-0.0041) 0.0025   (0.0021-0.0050) 0.69 
Effective dose 
(Sv/GBq) 
0.077     (0.062-0.138) 0.075     (0.051-0.167) 0.69 
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Supplementary Figure 1. Images from patient 3 showing axial 177Lu-PP-F11N SPECT/CT 
scans (A,E,I) of suspicious lymph nodes (red arrows), with corresponding histology and in 
vitro autoradiography results in the same row: fraction of hematoxylin-eosin-stained sections 
(B,F,J) together with autoradiograms indicating total binding of 111In-PP-F11N (C,G,K) and 
non-specific binding (D,H,L). M and N show dog stomach tissue as a positive control. First 
row: 8 x 8 mm lesion without uptake in SPECT/CT (A, red arrow) corresponds to a lymph 
node metastasis with 40% tumor cells (B) with specific 111In-PP-F11N binding (C and D). 
Second row: 9 x 9 mm lesion with uptake in SPECT/CT (E, red arrow) corresponds to a 
lymph node metastasis with 60% tumor cells (F) with specific 111In-PP-F11N binding (G and 
H). Third row: 16 x 18 mm lesion with uptake in SPECT/CT (I, red arrow) corresponds to a 
lymph node metastasis with 40% tumor cells (J) with specific 111In-PP-F11N binding (K and 
L). Red bars: 10 mm. 
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